Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Organisation › Details

T-Knife GmbH

T-knife is a next-generation adoptive T-cell company utilizing its proprietary humanized T-cell receptor (HuTCR) mouse platform technology to treat solid tumors. It was founded as a spin-off from Max-Delbruck Center for Molecular Medicine with support of Charité University Hospital in Berlin in 2018. Ascenion GmbH, technology transfer partner of MDC and Charité, accompanied the scientists from the beginning, continuously expanded the patent base, supported the acquisition of pre-seed funding and the negotiation of collaboration and license agreements in coordination with MDC and Charité. T-knife ´s mission is to use its unique technology to bring highly effective and safe T-cell receptor- based therapeutics to market. Based on the unparalleled T-cell immunology expertise of its founders and the unique and proprietary HuTCR platform, the Company develops fully human TCRs which are expected to set new technology standards and to provide superior safety and efficacy. The Company has demonstrated pre-clinical proof-of-concept and its lead TCR has entered clinical development. In addition, T-knife has validated the platform for over 90 undisclosed cancer targets, with several follow-on drug candidates being already in preclinical development. The Company expects to bring three additional TCRs into the clinic by 2022. T-knife is executing a two-pronged corporate growth strategy: developing an internal pipeline of best- in-class therapeutics and in parallel, establishing external partnerships by out-licensing already patented TCRs and/or providing the Company’s HuTCR mouse for unbiased discovery of new epitopes. T-knife is backed by top tier investors Versant Ventures, RA Capital, Andera Partners, and Boehringer Ingelheim Venture Fund. *

 

Period Start 2018-03-13 reorganised
  Predecessor T-Knife UG (haftungsbeschränkt)
Products Industry T cell therapy
  Industry 2 HuTCR transgenic mouse platform (T-Knife)
Persons Person Kieback, Elisa (T-Knife 201711– Managing Director + Co-Founder)
  Person 2 Blankenstein, Thomas (Helmholtz 202008 Prof at MDC Berlin + Co-Founder of T-Knife GmbH)
     
Region Region Berlin
  Country Germany
  Street 10 Robert-Rössle-Str.
  City 10405 Berlin
  Tel +49-30-94892432
    Address record changed: 2020-08-06
     
Basic data Employees n. a.
     
    * Document for �About Section�: T-Knife GmbH. (8/6/20). "Press Release: T-Knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies". Berlin.
     
   
Record changed: 2020-10-11

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for T-Knife GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top